Could a new drug beat the standard for preventing postpartum hemorrhage?

NCT ID NCT06333340

Recruiting now Disease control Sponsor: Samuel Lunenfeld Research Institute, Mount Sinai Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether carbetocin works better than oxytocin to prevent severe bleeding after a planned C-section in women with risk factors like twins, a large baby, or obesity. About 160 participants will receive one of the two drugs, and doctors will measure how many need extra medication to control bleeding. The goal is to find a more effective option for those at higher risk.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Carbetocin and oxytocin
What this could lead to: If carbetocin works better, it could reduce dangerous bleeding after C-sections in high-risk women.
What could go wrong: This is a small, early-phase trial (160 participants) and may not prove carbetocin is superior. Both drugs have known side effects like nausea or low blood pressure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POST PARTUM HEMORRHAGE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Postpartum Hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POST PARTUM HEMORRHAGE

Contacts and locations

Locations

Mount Sinai Hospital
RECRUITING

Toronto, Ontario, M5G1X5, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.